Filing search / Innovation Pharmaceuticals Inc. / "Retention"

8-K

EX-10.1

IPIX Innovation Pharmaceuticals Inc.

15 Jun 22

Entry into a Material Definitive Agreement

4:00pm

of the proceeds of such proposed Transaction as determined pursuant to the provisions of Article 7.3 above); and (ii) any bonus, retention payment

8-K

EX-99.1

520uoyhi9bl

13 Feb 20

Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints; Positive Topline Results of Oral Brilacidin

4:05pm

POS AM

ydr6vzhigchmqj

17 Oct 19

Prospectus update (post-effective amendment)

5:23pm

8-K

EX-99.1

l1hg3rmg 06i0j

22 Jul 19

Entry into a Material Definitive Agreement

9:30am

8-K

EX-99.1

hjedieft l62cbosc

16 May 19

Regulation FD Disclosure

10:15am

8-K

EX-2.1

hl8ma0lmqbkyf98c4n

9 Sep 13

Cellceutix Acquires PolyMedix Assets From Bankruptcy Court, Gains Ownership of Two Clinical Stage Drugs, Multiple Compounds, and Equipment Assets

12:00am